1851 Harbor Bay Parkway
735 articles with Exelixis, Inc.
11/18/2019The companies included on this list are the top ten companies headquartered in Biotech Bay based on 2018 revenue.
Exelixis’ Partner Ipsen Announces Health Canada’s Approval of CABOMETYX® (cabozantinib) Tablets for the Treatment of Patients With Previously Treated Advanced Hepatocellular Carcinoma
Exelixis, Inc. (NASDAQ:EXEL) today announced that its partner Ipsen Biopharmaceuticals Canada Inc. received Health Canada approval of CABOMETYX® (cabozantinib) tablets for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.
Exelixis, Inc. announced that Michael M. Morrissey, Ph.D., the company’s President and Chief Executive Officer, will provide a corporate overview at the Stifel 2019 Healthcare Conference being held next week in New York.
Exelixis’ Collaborator Daiichi Sankyo Announces Positive Results From Phase 3 Pivotal Trial of Esaxerenone in Patients With Diabetic Nephropathy
-- Results being presented today in a late-breaking presentation (abstract TH-PO1201) at Kidney Week 2019, the annual meeting of the American Society of Nephrology in Washington, D.C.
Invenra Inc. announced that it has expanded its collaboration with Exelixis, Inc.
Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the third quarter of 2019 and provided an update on progress toward fulfilling its key corporate objectives, as well as commercial and clinical development milestones.
Conference Call and Webcast to Follow at 5:00 p.m. EDT / 2:00 p.m. PDT
Calithera Biosciences Completes Patient Enrollment in Randomized CANTATA Trial of Telaglenastat and Cabozantinib in Advanced Renal Cell Carcinoma
Top-line results expected in second half of 2020
Exelixis, Inc. (Nasdaq: EXEL) today announced that members of Exelixis management will provide a corporate overview at the 2019 Cantor Global Healthcare Conference, which is being held next week in New York. Exelixis’ presentation has been scheduled for Wednesday, October 2, 2019 at 8:55 AM EDT / 5:55 AM PDT.
Exelixis to Present at the Morgan Stanley 17th Annual Global Healthcare Conference on September 10, 2019
Exelixis, Inc. (Nasdaq: EXEL) today announced that Michael M. Morrissey, Ph.D., the company’s President and Chief Executive Officer, will provide a corporate overview at the Morgan Stanley 17th Annual Global Healthcare Conference
Exelixis, Inc. reported financial results for the second quarter of 2019 and provided an update on progress toward fulfilling its key corporate objectives, as well as discovery, development and commercial milestones.
Exelixis and Aurigene Enter Into Exclusive Collaboration, Option and License Agreement to Discover and Develop Novel Therapies for Cancer
Companies will partner to advance small molecules in up to six discrete projects, including three existing programs against specific predetermined targets
Exelixis, Inc. (NASDAQ: EXEL) announced today that its second quarter 2019 financial results will be released on Wednesday, July 31, 2019 after the markets close.
Exelixis Updates Phase 1b COSMIC-021 Trial of Cabozantinib in Combination With Atezolizumab in Patients With Advanced Solid Tumors
Original metastatic castration-resistant prostate cancer and immunotherapy-refractory non-small cell lung cancer cohorts expanded to 80 subjects
The Phase III trial paired Exelixis and Genentech's Cotellic with a checkpoint inhibitor in advanced melanoma.
Exelixis, Inc. (Nasdaq: EXEL) today announced that the company will be presenting at the following three investor conferences in June 2019:
Exelixis and Iconic Therapeutics Enter into Exclusive Option and License Agreement for Novel Antibody-Drug Conjugate Program
ICON-2 program targets Tissue Factor (TF) with potential broad impact in oncology
Exelixis, Inc. (Nasdaq: EXEL) today announced that the company will be presenting at the following two investor conferences on Tuesday, May 21, 2019, in New York:
First commercial sale triggers $20 million milestone payment to Exelixis
Exelixis Initiating Phase 3 Pivotal Trial (COSMIC-313) of Cabozantinib in Combination with Nivolumab and Ipilimumab Versus Nivolumab and Ipilimumab in Previously Untreated Advanced Renal Cell Carcinoma
COSMIC-313 is the third phase 3 pivotal trial to investigate cabozantinib in combination with immune checkpoint inhibitors